Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Infectious Diseases and Therapy|September 15, 2025
The Effects of Cobicistat and Voriconazole on the Safety, Pharmacokinetics, and Pharmacodynamics of the TLR7 Agonist Vesatolimod in People with HIVYanan Zheng, Mary Wire, Robert Were Omange, et al.
Clinical and Vaccine Immunology : CVI|December 30, 2011
Human endogenous retrovirus K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected in HIV-1-infected subjects using standard peptide matrix-based screeningR Brad Jones, Vivek M John, Diana V Hunter, et al.
The Lancet. HIV|March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyEdwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 3, 2015
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyAnton Pozniak, Jose R Arribas, Joseph Gathe, et al.
The Lancet. HIV|March 6, 2017
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyChloe Orkin, Edwin DeJesus, Moti Ramgopal, et al.
The Lancet. HIV|December 3, 2020
Multi-stakeholder consensus on a target product profile for an HIV cureSharon R Lewin, Timothy Attoye, Cathy Bansbach, et al.
Infectious Diseases and Therapy|September 15, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist VesatolimodSharon A Riddler, Constance A Benson, Cynthia Brinson, et al.
Journal of Virology|April 29, 2011
Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infectionDevi SenGupta, Ravi Tandon, Raphaella G S Vieira, et al.
Science Translational Medicine|June 24, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapyDevi SenGupta, Cynthia Brinson, Edwin DeJesus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2020
Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1Sharon A Riddler, Michael Para, Constance A Benson, et al.
Pageof 4